MedTrace Logo

Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in Managing of Oral Lesions in Patient With Pemphigus Vulgaris.

NCT07641725 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-06-11

No results posted yet for this study

Summary

Pemphigus vulgaris (PV) is a chronic, potentially life-threatening autoimmune mucocutaneous disorder that significantly impairs patients' quality of life. While systemic corticosteroids and immunosuppressants remain the standard of care, many patients suffer from persistent, painful oral lesions that exhibit delayed healing or poor response to conventional systemic protocols. This clinical trial investigates the efficacy and safety of supportive topical interventions: clobetasol propionate 0.05% mouthwash and photobiomodulation therapy (PBMT)-a non-invasive approach designed to accelerate tissue repair, and their combination. The primary objective is to identify effective adjunctive topical therapies that can facilitate the healing of oral erosions, mitigate pain, and potentially allow for a reduction in systemic medication dosages, thereby minimizing long-term treatment-related complications and improving overall patient outcomes.

Conditions

  • Oral Lesions in Patients With Pemphigus Vulgaris

Interventions

DRUG

Clobetasol propionate 0.05% Mouthwash

Participants will receive topical clobetasol propionate 0.05% mouthwash

DEVICE

diode laser for photobiomodulation

Participants will receive photobiomodulation therapy (low-level laser therapy) by diode laser.

DRUG

clobetasol propionate 0.05% mouthwash + photobiomodulation

Participants will receive combined treatment with topical clobetasol propionate 0.05% mouthwash and photobiomodulation therapy (low-level laser therapy) by diode laser.

Sponsors & Collaborators

  • Damascus University

    lead OTHER

Principal Investigators

  • Abeer Aljoujou, PhD In Oral medicine · Associate Professor, Department of Oral Medicine, Faculty of Dental medicine, Damascus University, Damascus, Syria.

  • Nemat Alsaghir, PhD in dermatology · Lecturer, Department of Dermatology, Faculty of Medicine, Damascus University, Damascus, Syria.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-09-01
Completion
2026-12-01

Countries

  • Syria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07641725 on ClinicalTrials.gov